THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today announced the pricing of an underwritten public offering of 4,146,500 units at a price to the public of $2.05 per unit, for gross proceeds of $8,500,325. Each unit consists of one share of common stock and a warrant to purchase four-tenths (0.40) of a share of common stock. The shares of common stock and warrants are immediately separable and will be issued separately such that no units will be issued.
